

ASX / BWX

ASX Announcement

3 January 2018

EXERCISE OF PERFORMANCE OPTIONS

Melbourne, Australia - BWX Limited (ASX: BWX)

In the accompanying Appendix 3B, the Company provides details in relation to the exercise of options for 1,000,000 ordinary shares at \$2.00 per share. The options were previously issued to a former Director of the Company at the inception of BWX during 2013 and prior to the Company's listing on the ASX.

- ENDS -

About BWX

ASX listed, BWX Limited is a vertically integrated developer, manufacturer, distributor and marketer of branded skin and hair care products with an emphasis on the natural segment of the beauty and personal care market.

The company owns, produces, and distributes under the Sukin, Andalou Naturals, Mineral Fusion, Life Basics, DermaSukin, Uspa, Edward Beale, and Renew personal care brands as well as the Nourished Life online marketplace.

For further information please contact:

John Humble

Chief Executive Officer and Managing Director

E: john.humble@bwxltd.com

T: +61 3 8785 6300

Genevieve Milesi

Investor Relations

E: gm@mileconsult.com.au

T: +61422 286 207

Aaron Finlay Finance Director

E: aaron.finlay@bwxltd.com

T: +61 3 8785 6300

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced\ 01/07/96\ \ Origin: Appendix\ 5\ \ Amended\ 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13$

BWX L	IMITED	
ABN 13 163	3 488 631	
We (th	ne entity) give ASX the following in	nformation.
	1 - All issues st complete the relevant sections (attach s	heets if there is not enough space).
1	*Class of *securities issued or to be issued	Fully Paid Ordinary Shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	500,000 (1) 500,000 (2)
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Options are being exercised under the Company's Performance Option Terms.
	and dates for conversion)	

Name of entity

24/10/2017 Appendix 3B Page 2

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
5	Issue price or consideration	\$2.00 (1)&(2)
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Shares are being issued in accordance with the Company's Performance Option Terms.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	No
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A

⁺ See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
7	⁺ Issue dates	20 December 2017 (1)	
,	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	3 January 2018 (2)	
	Cross reference: item 33 of Appendix 3B.		
		· · · · · · · · · · · · · · · · · · ·	
0		Number	+Class
8	Number and +class of all +securities quoted on ASX (including the +securities in	115,341,328	Fully Paid Ordinary Shares
	section 2 if applicable)	3,846,942	Fully Paid Ordinary shares subject to voluntary escrow
		3,043,000	Fully Paid ordinary shares issued in accordance with the Company's Employee Loan Plan

⁺ See chapter 19 for defined terms.

		Number	+Class
9	Number and +class of all	970,000	Options exercisable
	+securities not quoted on ASX		at \$2.00 and expiring
	(including the *securities in section 2 if applicable)		30 September 2018
	section 2 if applicable)		
10	Dividend policy (in the case of a	N/A	
	trust, distribution policy) on the increased capital (interests)		
	mereased capital (interests)		
Part :	2 - Pro rata issue		
11	Is security holder approval	N/A	
11	required?	N/A	
12	Is the issue renounceable or non-	N/A	
12	renounceable?	11/11	
10			
13	Ratio in which the *securities will be offered	N/A	
	50 01101 04		
14	*Class of *securities to which the	N/A	
	offer relates		
15	⁺ Record date to determine	N/A	
	entitlements		
16	Will holdings on different	N/A	
10	registers (or subregisters) be	14/11	
	aggregated for calculating entitlements?		
	enducinents:		
17	Policy for deciding entitlements in	N/A	
	relation to fractions		
18	Names of countries in which the	N/A	
	entity has security holders who will not be sent new offer		
	documents		
	Note: Security holders must be told how their		
	entitlements are to be dealt with. Cross reference: rule 7.7.		
19	Closing date for receipt of	N/A	

acceptances or renunciations

⁺ See chapter 19 for defined terms.

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

⁺ See chapter 19 for defined terms.

32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	N/A
33	⁺ Issue	e date	N/A
	-	uotation of securiti	
34	Type (tick o	of ⁺ securities one)	
(a)	✓	⁺ Securities described in Part	1
(b)			nd of the escrowed period, partly paid securities that become fully paid en restriction ends, securities issued on expiry or conversion of convertible
		t have ticked box 34(a) ecurities forming a new c	lass of securities
Tick to docume		e you are providing the informat	ion or
35			securities, the names of the 20 largest holders of the che number and percentage of additional *securities
36			y securities, a distribution schedule of the additional imber of holders in the categories
37		A copy of any trust deed for	the additional ⁺ securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought		
39	⁺ Class of ⁺ securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and ⁺ class of all	Number	⁺ Class
74	*securities quoted on ASX (including the *securities in clause 38)		

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the
 +securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	(Director/Company secre	3 January 2018
Print name:	Aaron Finlay	

6/12/2017

⁺ See chapter 19 for defined terms.